Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas
CXCR4
Adult
Male
Receptors, CXCR4
0303 health sciences
Neurofibroma
Neurofibromatosis 1
Adolescent
Plexiform neurofibroma
S100 Proteins
CXCL12
Chemokine CXCL12
3. Good health
Gene Expression Regulation, Neoplastic
Young Adult
03 medical and health sciences
Child, Preschool
Humans
Female
Schwann Cells
Child
Neurofibromatosis type 1
DOI:
10.1007/s00381-018-3745-6
Publication Date:
2018-02-17T02:40:09Z
AUTHORS (7)
ABSTRACT
Neurofibromatosis type 1 (NF1) is a common autosomal dominantly inherited disorder that affects both the skin and the nervous system. NF1 occurs due to the mutations in the NF1 gene. Neurofibromas are the most common Schwann cell-based tumors in NF1 patients, which are mainly categorized into dermal and plexiform neurofibromas. Studies on different tumor types demonstrate that CXCR4 expression increases in tumor tissues and is linked to metastasis and cancer progression.In the present study, we aimed to analyze the gene expression of CXCR4, and its ligand CXCL12, in human neurofibromas.Eight NF1 patients aged between 5 and 37 (2 males, 6 females) were selected. The patient group comprised 1 plexiform neurofibroma, 1 pheochromocytoma, and 6 dermal neurofibromas. Following pathological examination and diagnosis, tumors were co-stained with antibodies against Schwann cell marker S100 and target molecule CXCR4. CXCR4 expression in Schwann cell-based tumors was detected at the protein level. RNA isolated from the same tumors was used for RT-PCR-based studies to measure the quantitative expression of CXCR4 and CXCL12.CXCR4 gene expression increased 3- to 120-fold and CXCL12 gene expression increased 33- to 512-fold in all human Schwann cell-based tumors.In order to validate the role of CXCR4 and its relationship with CXCL12 in NF1, future studies should be performed with additional tumors and different tumor types.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (21)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....